These findings are consistent with our previous findings in Irg1-deficient immunocompetent mice (Chen et al., 2023), and reinforce the notion that targeting IRG1 present a promising therapeutic strategy for cancer treatment, not only in mouse models but also in the context of the human immune system. The gene discussed is ACOD1; the disease is cancer.